Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Melanoma 68Carcinoma, Non-Small-Cell Lung 41Carcinoma, Renal Cell 36Neoplasm Metastasis 22Carcinoma, Hepatocellular 15Neoplasms 14Colorectal Neoplasms 13Brain Neoplasms 13Skin Neoplasms 12Squamous Cell Carcinoma of Head and Neck 11Pancreatic Neoplasms 10Lung Neoplasms 10Kidney Neoplasms 10Uveal Melanoma 9Ovarian Neoplasms 9Urinary Bladder Neoplasms 8Sarcoma 8Prostatic Neoplasms 8Carcinoma, Transitional Cell 8Mesothelioma 7Glioblastoma 7Clear-cell metastatic renal cell carcinoma 7Carcinoma, Merkel Cell 7Recurrence 6Colonic Neoplasms 6Triple Negative Breast Neoplasms 5Small Cell Lung Carcinoma 5Myelodysplastic Syndromes 5Multiple Myeloma 5Mesothelioma, Malignant 5

Interventions

Gemcitabine 3Cisplatin 3Carboplatin 3pembrolizumab 2erdafitinib 2vinflunine 1tremelimumab 1enfortumab vedotin 1durvalumab 1avelumab 1atezolizumab 1Tiragolumab 1Nivolumab 1Midazolam 1Metformin 1Ipilimumab 1Docetaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Urothelial Cancer × Ipilimumab × 1 year × Clear all
NCT03036098 2026-03-06

CheckMate901

Bristol-Myers Squibb

Phase 3 Active not recruiting
1,314 enrolled 23 charts 1 FDA
Genitourinary

Urothelial Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡